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Background.Renal dysfunction in end-stage liver disease (ESLD) results from systemic conditions that affect both liver and kid-
ney with activation of vasoconstrictor systems. In this setting, estimated glomerular filtration rate (eGFR) may undergo variations
often outside Kidney Disease Improving Global Outcomes criteria for acute kidney injury (AKI) diagnosis, whose meaning is not
clear. The aim of this study was to evaluate eGFR variations in ESLD outpatients listed for liver transplant (liver Tx) and the asso-
ciation with post-Tx outcome.Methods. Fifty-one patients with ESLD were retrospectively evaluated from listing to transplant
(L-Tx time), intraoperatively (Tx time), and up to 5 years post-Tx time. Variations between the highest and the lowest eGFR occur-
ring in more than 48 hours, not satisfying Kidney Disease Improving Global Outcomes guideline, were considered as fluctuations
(eGFR-F). Fluctuations of eGFR greater than 50%were defined as eGFR drops (DeGFR). Early graft dysfunction, AKI within 7 days,
chronic kidney disease, and short- and long-term patient survivals were considered as outcomes. Results. All patients pre-
sented eGFR-F, whereas DeGFR were observed in 18 (35.3%) of 51 (DeGFR+ group). These patients presented higher levels
of Model for End-stage Liver Disease score, pre-Tx bilirubin and significantly greater incidence of post-Tx AKI stages 2 to 3 com-
pared with patients without drops (DeGFR−). DeGFRwas the only independent predictive factor of the occurrence of post-Tx AKI.
The occurrence of AKI post-Tx was associated with the development of chronic kidney disease at 3 months and 5 years post-Tx.
Conclusions.Drops of eGFR are more frequently observed in patients with a worse degree of ESLD and are associated with a
worse post-Tx kidney outcome.
(Transplantation Direct 2017;3: e222; doi: 10.1097/TXD.0000000000000733. Published online 10 October, 2017.)Renal dysfunction in end-stage liver disease (ESLD) canoccur as a result of systemic conditions that affect both
liver and kidney.1 The progression of liver cirrhosis to severeReceived 1 April 2017. Revision requested 20 July 2017.
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FIGURE 1. Process of patient selection. pre-Tx, before liver trans-
plantation; L-Tx time, from listing to transplant time; Tx time, intraop-
eratively time; post-Tx time, up to 5 years postoperatively.
2 Transplantation DIRECT ■ 2017 www.transplantationdirect.comto chronic kidney ischemia.3 In these scenario, patients are
particularly prone to glomerular filtration rate (GFR) reduc-
tion with acute variations of serum creatinine (sCr) from
baseline.4 Changes in sCr have been recently reported to ex-
ert poor impact on patient's survival as demonstrated in
nephrologic setting and should be considered.1,4
A variation of sCr of 0.3 mg/dL or greater from baseline
within 48 hours has been validated by Kidney Disease Im-
proving Global Outcomes (KDIGO) guideline as a criterion
to define acute kidney injury (AKI).5 In patients with ESLD,
AKI has been associated with increased mortality and wors-
ening of kidney function before and after liver transplanta-
tion (liver Tx).4,6,7 Moreover, AKI has been recognized as
an independent risk factor of post-Tx de novo chronic kidney
disease (CKD).8 Cirrhotic patients are characterized by an in-
stable estimated-GFR (eGFR), with frequent isolated de-
creases. This is usually related to prerenal AKI, due to high
dose of diuretics, acute infections, decompensated ascites,
electrolyte and water imbalance, spontaneous bacterial peri-
tonitis, and gastrointestinal bleedings, as can be diagnosed
in hospitalized patients.1 However, most patients with liver
cirrhosis are managed as outpatients. In this setting, the as-
sessment of parameters required for AKI diagnosis, such as
baseline eGFR, its variations, and timing during follow-up,
is challenging. As a result, AKI diagnosis according to
KDIGO guideline is difficult due to the short time of observa-
tion required (48 hours),5 generally not feasible in outpa-
tients monitoring. The presence of isolated decreases of
eGFR in patients with ESLD and their effects on renal func-
tion before and after liver Tx have been poorly studied and
not completely clarified.
Therefore, the aim of this study was to evaluate eGFR var-
iations in ESLD and investigate the association with post-Tx
outcome, in terms of early and long-term renal function and
patient survival.MATERIALS AND METHODS
This is a single-center study from a cohort of 112waitlisted
patients for liver Tx in the Liver Unit of Sapienza University
of Rome. From this cohort, all patients transplanted (whole
liver) from donation after brain-death donors from October
2008 to October 2011 were considered (59 patients). Acute
liver failure (4 patients) and combined liver-kidney Txs (4 pa-
tients) were excluded (Figure 1).
We retrospectively evaluated 51 liver Tx recipients as fol-
lows: from listing to Tx (L-Tx time), intraoperatively (Tx
time) and up to 5 years post-Tx time.
Data Collected From L-Tx Time
During L-Tx time, patients were clinically assessed every
3 months in the outpatient setting on the basis of the
nephrologic form developed in our renal outpatient clinic,9
with blood test done every 4 to 6 weeks.
Renal functionwas evaluated assessing sCr levelmeasured by
enzymatic assay and GFR estimated by the 4 variables ofMod-
ification of Diet in Renal Disease 4 formula Study equation.10
CKD was defined as a reduction of the eGFR less than
60 mL/min per 1.73 m2 longer than 3 months and classified
in stages according to KDIGO guidelines. Worsening of
CKD was defined as progression to a higher CKD stage.11
We considered in each patient:• eGFR at listing (eGFR-list);
• eGFR at Tx (eGFR-Tx);
• maximum eGFR (eGFR-max) defined as the highest value of
GFR estimated on the basis of the lowest value of sCr collected
during L-Tx time. It was considered as the baseline eGFR ac-
cording to KDIGO guideline5 and the looking back reference,
standard method12;
• minimum eGFR (eGFR-min) defined as the lowest value of
GFR estimated on the basis of highest value of sCr collected
during L-Tx time;
• variations of eGFR observed during L-Tx timewere defined as
fluctuations of eGFR (eGFR-F). These were considered as a
percentage of variation between the lowest and the highest
eGFR, estimated on the basis of maximum and minimum
value of sCr among all values collected, respectively. Fluctua-
tions of eGFR, more than 50% from maximum, were defined
as eGFR drops (DeGFR).
Data Collected Intraoperatively During Liver
Transplantion (Tx Time)
Data regarding the number of transfused units of packed
red blood cell, fresh-frozen plasma, crystalloids or colloids,
inotropic drug administered during Tx time, and the donor
risk index (DRI) score were collected.
Data Collected Post-Tx Time
We evaluated post-Tx early renal function considering the
occurrence of AKI according to KDIGO guideline as an in-
crease in sCr by ≥ 0.3 mg/dL within 48 hours or an increase
in sCr to ≥ 1.5 times baseline within the prior 7 days. AKI
was classified into 3 stages: stage 1, increase of 0.3 mg/dl or
greater or increase of 1.5- to 1.9-fold from baseline; stage 2,
increase of twofold to 2.9-fold from baseline; stage 3, in-
crease of more than threefold from baseline or 4.0 mg/dL
or greater with an acute increase of at least 0.5 mg/dL or on
renal replacement therapy.5
The occurrence of post-Tx CKD (at 6, 12, 24, 36,
60 months) was evaluated and staged according to the
KDIGO guidelines.13
Early graft function was evaluated considering levels of as-
partate aminotransferase, alanine aminotransferase, serum
bilirubin, and International Normalized Ratio (INR) within
7 days post-Tx. We defined early graft dysfunction as the
TABLE 1.
Demographic and clinical characteristics of 51 liver transplant
recipients at L-Tx time and at Tx-time
L-Tx time Tx-time
Age, y 57.8 (50.1-61.0) 56.0 (51.1-61.3)
Gender (female) 8 (15.7) 8 (15.7)
BMI, kg/m2 26.5 (22.6-31.1) 26.0 (23.6-30.8)
Hepatitis C virus 20 (39) 20 (39)
Alcoholic cirrhosis 7 (13.7) 7 (13.7)
Biliary sclerosis 3 (5.9) 3 (5.9)
Hepatocarcinoma 17 (33.3) 17 (33.3)
Diabetes 17 (33.3) 17 (33.3)
Hypertension 5 (9.8) 5 (9.8)
CKD 8 (15.7) 8 (15.7)
Ascites 20 (39.2) 20 (39.2)
Lab-MELD score 15.0 (11.0-19.0) 16.0 (13.0-22.0)
Bilirubin, mg/dL 2.9 (1.6-4.8) 3.0 (1.7-7.6)
INR 1.4 (1.3-1.6) 1.5 (1.3-1.8)
sCr, mg/dL 0.9 (0.7-1.0) 0.9 (0.6-1.1)
eGFR, mL/min 92.1 (71.3-108.2) 94.2 (73.6-142.4)
G1 (≥90) 26 (51.0%) 29 (56.9%)
G2 (60-89) 20 (39.2%) 15 (29.4%)
G3a (45-59) 3 (5.9%) 3 (5.9%)
G3b (30-44) 1 (2.0%) 3 (5.9%)
G4 (15-29) 1 (2.0%) 1 (2.0%)
G5 (<15) 0 0
Data are presented as median (IQR) and frequency (percentage) as appropriate.
BMI, body mass index; G1, GFR≥ 90 mL/min; G2, GFR = 60-89 mL/min; G3a, GFR = 45-59 mL/min;
G3b, GFR = 30-44 mL/min; G4, GFR = 15-29 mL/min; G5, GFR <15 mL/min.
© 2017 Wolters Kluwer Fiacco et al 3presence of 1 or more of the following parameters: (i) total
bilirubin ≥10 mg/dL on post-Tx day 7, (ii) INR of 1.6 or
greater on post-Tx day 7, and (iii) aspartate aminotransferase
or alanine aminotransferase of 2000 IU/mL or greater within
the first week post-Tx.14
All patients received an immunosuppressive regimen based
on intravenous basiliximab (20 mg) on postoperative days 0
and 4; mycophenolate mofetil if leucocytes were greater than
4000/mm3 and delayed introduction of tacrolimus from post-
operative day 5. The immunosuppressionwas adjusted in case
of persisting renal dysfunction 7 days after liver Tx. Three
months and 5 years post-Tx patient survivals were considered.
Statistical Analysis
Data are presented as median and interquartile range
(IQR) for continuous variables and as frequency and percent-
age for categorical variables. Nonparametric methods were
used for inferential analysis. The Mann-Whitney, Kruskal-
Wallis, or Wilcoxon tests were used to compare distribution
of continuous variables as appropriate. The Fisher exact
and the χ2 tests were used to evaluate associations between
categorical variables, as appropriate. A univariate analysis
was first performed to identify variables associated with each
outcome considered. Odds ratio and 95% confidence inter-
vals were estimated. A multivariate logistic regression was
performed to identify independent predictors of outcome.
The Cox regression model was used to determine the risk of
death within 5 years post-Tx. All tests were performed using
SPSS system 22.0 (SPSS Inc, Chicago, IL) with a P value less
than 0.05 considered significant.RESULTS
Demographic and clinical characteristics of the 51 recipi-
ents at listing and Tx are shown in Table 1. The median
L-Tx time was 254 days (IQR, 92-509).
Amean of 8 ± 3 tests were performed to assess patients' re-
nal function during L-Tx time. All patients presented eGFR-F,
ranging from median eGFR-max of 126.52 mL/min per
1.73 m2 (IQR, 104.00-150.00) to median eGFR-min of
66.57 mL/min per 1.73 m2 (IQR, 51.84-91.18).
EstimatedGFR-Tx did not have a significantly different re-
sult compared with eGFR-list (P = 0.960). In all patients,
eGFR-max never matched with eGFR-list or eGFR-Tx.
Drops of eGFRwere observed in 18 (35.3%) of 51 recipients.
According to the presence of DeGFR, patients were divided
into 2 groups: DeGFR+ and DeGFR−. Clinical parameters
at L-Tx time, Tx time, and post-Tx time of the 2 groups
(DeGFR+ vs DeGFR−) are reported in Table 2.
The number of sCr tests did not result in a difference be-
tween the 2 groups (P = 0.880). The DeGFR+ group pre-
sented a higher prevalence of CKD at listing compared with
the DeGFR− group (6/18 patients, 33% vs 2/33 patients,
6%; P = 0.017). In both groups, no patients developed de
novo CKD, neither a worsening of preexisting CKD, during
L-Tx time.
During L-Tx time, patients in the DeGFR+ group pre-
sented a significantly higher Model for End-stage Liver Dis-
ease (MELD) score both at listing (P = 0.025) and at Tx
(P = 0.033) compared with the DeGFR− group. Considering
the single parameters ofMELD score, significantly greater to-
tal bilirubin values at listing (P = 0.012) and at Tx (P = 0.047)were found in the DeGFR+ versus DeGFR− groups. No dif-
ferences in INR and body mass index were observed between
the 2 groups.
During Tx time, no differences in number of transfusions,
inotropic support (dopamine), and DRI score were found in
the DeGFR+ group compared with the DeGFR− group.
In post-Tx time, AKI occurred in 26 (51%)of 51 recipients.
Among them, 15 (58%) of 26 presented AKI stage 1, 8 (31%)
26 in stage 2, and 3 (11%) 26 in stage 3. In particular, AKI
stages 2 to 3 occurred in 8 (44%) of 18 DeGFR+ compared
with 3 (9%) of 33 DeGFR− recipients (P = 0.007) (Table 2).
Early graft dysfunction occurred in 14 (27%) of 51 recip-
ients with no differences between the 2 groups (P = 0.569).
The logistic regression analysis of predictors of post-Tx AKI
in 51 liver Tx recipients is reported in Table 3. Among all pre-
dictive factors, DeGFR only were associated with development
of AKI post-Tx (P = 0.007) on the univariate analysis. The
DeGFR+ group presented a higher prevalence of pre-Tx CKD
(P = 0.010) but the occurrence of AKI was not significantly dif-
ferent in patients with and without CKD (P = 0.244). The
multivariate logistic regression analysis, forced for age and
sex, demonstrated that DeGFR were the only independent
predictive factors of the occurrence of post-Tx AKI.
Estimated-GFR trend post-Tx (at 6, 12, 24, 36, 60months)
is shown in Figure 2. Patients with AKI post-Tx were associ-
ated with development of CKD from 3 months up to 5 years
post-Tx (P = 0.004) (Figure 3).
Among all predictive factors, DeGFRwere associated with
development of long-term CKD post-Tx on the univariate
analysis (P = 0.008) (Table 4).
TABLE 2.
Demographic and clinical parameters considered during L-Tx
time, Tx time, andpost-Tx time inDeGFR+versusDeGFR−group
DeGFR+ group 18 pts DeGFR− group 33 pts
Time L-Tx time p
Age (years) 53.0 (50.0-59.3) 56.0 (51.7-59.9) 0.541
BMI (kg/m2) 25.2 (23.7-29.8) 26.0 (24.1-30.0) 0.626
Hepatitis C Virus 8 (44.4) 14 (42.4) 0.889
Diabetes 6 (33.3) 11 (33.3) 0.625
Hypertension 2 (11.1) 3 (9.1) 0.817
eGFR-list (ml/min) 86.0 (67.5-131.8) 105.9 (81.0-124.9) 0.280
MELD-list 17.0 (14.0-20.0) 14.0 (11.0-17.0) 0.025
Bilirubin-list (mg/dl) 4.2 (2.7-6.0) 2.2 (1.5-3.89) 0.012
INR-list 1.44 (1.22-1.68) 1.37 (1.26-1.54) 0.269
sCr-list (mg/dl) 0.86 (0.65-1.00) 0.86 (0.76-1.20) 0.600
eGFR-Tx (ml/min) 78.8 (54.09-140.70) 106.28 (77.13-144.24) 0.233
MELD-Tx 20.0 (14.3-2.0) 15.0 (12.0-20.0) 0.033
Bilirubin-Tx (mg/dl) 6.7 (2.6-8.7) 2.6 (1.5-6.4) 0.047
INR-Tx 1.61 (1.28-1.92) 1.46 (1.31-1.56) 0.129
sCr-Tx (mg/dl) 0.95 (0.65-1.21) 0.80 (0.60-1.05) 0.464
CKD 6 (33.3) 2 (6.1) 0.010
Tx time
PRBCs (units) 5 (3-7) 5 (3-6) 0.298
FFP (units) 10 (7-18) 12 (8-17) 0.061
Dopamine (mcg/kg) 233 (0-615) 320 (0-850) 0.078
DRI 1.442 (1.033-1.755) 1.476 (1.187-1.786) 0.644
Post-Tx time
AKI post-Tx 10 (55.6) 16 (48.5) 0.629
Stages 2 and 3 8 (44.0) 3 (9.0) 0.007
Data are presented as median value (IQR) and frequency (percentage) as appropriate; p value were
estimated.
post-Tx time, up to 1 week postoperatively; MELD-list, MELD at listing; MELD-Tx, MELD at transplant;
Bilirubin-Tx, Bilirubin at transplant; Bilirubin-list, Bilirubin at listing; INR-list, INR at listing; INR-Tx, INR at
transplant; sCr-list, sCr at listing; sCr-Tx, sCr at transplant; PRBC, packed red blood cell; FFP, fresh
frozen plasma; Dopamine, total dose of dopamine administered during Tx time.
TABLE 3.
Univariate and multivariate logistic regression analysis of
predictors of post-Tx AKI in 51 liver transplant recipients
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
L-Tx time
Sex (female) 2.63 (0.52-13.32) 0.244 0.83 (0.13-5.38) 0.844
Age 1.00 (0.95-1.06) 0.988 1.01 (0.95-1.07) 0.716
eGFR-list 0.99 (0.97-1.01) 0.391
MELD-list 1.07 (0.93-1.24) 0.358
sCr-list 2.02 (0.21-19.44) 0.543
Bilirubin-list 1.04 (0.93-1.16) 0.480
4 Transplantation DIRECT ■ 2017 www.transplantationdirect.comThree-month patient survival post-Tx was 96.1% (49/51
patients). No difference in survival was evidenced between
the 2 groups (17/18, 94.4% in DeGFR+ vs 32/33, 97% in
DeGFR−; P = 0.648).
Survival at5yearspost-Txwas80.4%(41/51patients), divided
between the 2 groups as follows: 72.2% (13/18 patients) in
DeGFR+ versus 84.8% (28/33 patients) in DeGFR− (P = 0.220).INR-list 2.89 (0.48-17.37) 0.248
eGFR-max 1.01 (0.98-1.03) 0.645
eGFR-Tx 1.00 (0.99-1.01) 0.197
MELD-Tx 1.01 (0.91-1.13) 0.799
sCr-Tx 0.47 (0.08-2.69) 0.396
Bilirubin-Tx 1.02(0.95-1.10) 0.656
INR-Tx 1.71 (0.23-9.98) 0.550
CKD 2.63 (0.52-13.32) 0.244
DeGFR 8.00 (1.77-36.13) 0.007 8.87 (1.67-47.23) 0.011
Tx time
PRBCs 1.17 (0.98-1.40) 0.090
FFP 1.04 (0.97-1.11) 0.299
Dopamine 1.00 (0.99-1.01) 0.978
OR, 95% CI, and P value were estimated.
OR, odds ratio; 95% CI, 95% confidence intervals.DISCUSSION
Hemodynamic portal alterations in advanced cirrhosis in-
clude increased intrahepatic vascular resistance, splanchnic va-
sodilation, activation of vasoconstrictive, and antinatriuretic
systems.3 In this condition, patients are particularly prone to
develop variations of eGFR.15,16
In liver Tx recipients, variations of eGFR have been exten-
sively studied in the post-Tx period.17-19 Sustained reduc-
tions, defined as rapid loss or abrupt decline of eGFR, have
been demonstrated and studied at different time post-Tx.18
These so-called events of eGFR have been associated with ad-
verse clinical outcomes post-Tx.17,19Kidney susceptibility to risk factors for renal damage is
clinically highlighted by unstable eGFR in patients with
ESLD, as it is frequently detected.20 KDIGO guideline has
been recently validated and proposed for nephrologic moni-
toring in patients with liver cirrhosis.5 The Modification of
Diet in Renal Disease 4 formula, a sCr-dependent formula,
has been accepted to estimate GFR, showing the greater ac-
curacy among different estimating equations.21
Most patients with liver cirrhosis are managed as outpa-
tients. In this setting, the assessment of parameters required
for AKI diagnosis, such as baseline eGFR, its variations,
and timing during follow-up, are challenging.
Fluctuations of eGFR were present in all our patients,
ranging from the median eGFR-max value of 127 mL/min
per 1.73 m2 to the eGFR-min of 67 mL/min per 1.73 m2.
This range despite CKD patients results from combination
of eGFR of patients affected by CKD (16%) and eGFR of pa-
tients with hyperfiltration (Hy) secondary to abnormal low
sCr.22-24 Hyperfiltration has been recognized as an important
predictor of worst outcome and may result from the marked
reduced hepatic synthesis of creatine due to the advanced de-
gree of cirrhosis. For this reason, a low sCr level can be con-
sidered a marker of poor hepatic function.
Serum creatinine is a surrogate of renal function (eGFR)
and is considered biased in patients with ESLD because of de-
creased hepatic synthesis of creatine, malnutrition, reduced
muscle mass, low BMI, female gender, interference of high
bilirubin values with sCr laboratory assay.25,26 Nevertheless,
in our study, sCr determination was performed with an enzy-
matic assay test instead of a colorimetric test because of biliru-
bin interference only for serum value greater than 20 mg/dL
reported by technical specifications of the Laboratory
FIGURE 2. Estimated-GFR trend 5 years posttransplantation in
all 51 liver transplant recipients. Time post-Tx at 6, 12, 24, 36,
60 months postoperatively.
TABLE 4.
Univariate and multivariate logistic regression analysis of
independent predictors of post-Tx CKD in 51 liver Tx recipients
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
L-Tx time
Sex (female) 2.55 (0.31-20.99) 0.383
Age 1.07 (0.96-1.18) 0.200
eGFR-list 0.98 (0.95-1.01) 0.157
MELD-list 0.99 (0.84-1.17) 0.931
sCr-list 12.16 (0.67-218.13) 0.090
Bilirubin-list 0.94 (0.76-1.17) 0.606
INR-list 1.04 (0.13-8.17) 0.966
eGFR-max 0.98 (0.96-1.00) 0.165
eGFR-Tx 0.96 (0.94-0.99) 0.022 0.91 (0.79-1.04) 0.150
MELD-Tx 1.04 (0.93-1.18) 0.475
sCr-Tx 23.99 (1.40-409.87) 0.028 0.01 (0.00-570.90) 0.190
Bilirubin-Tx 0.94 (0.80-1.09) 0.429
INR-Tx 0.93 (0.09-9.71) 0.953
CKD pre-Tx 13.71 (1.31-143.44) 0.029
DeGFR 4.80 (1.03-22.37) 0.046 7.04 (0.88-56.48) 0.060
Tx time
PRBCs 1.07 (0.94-1.23) 0.285
FFP 1.03 (0.96-1.11) 0.409
Dopamine 1.00 (0.98-1.08) 0.345
Post-Tx time
AKI post-Tx 1.97 (0.36-10.82) 0.436
OR, 95% CI, and P value were estimated.
© 2017 Wolters Kluwer Fiacco et al 5Method. None of our patients presented these high values of
bilirubin, as shown in Table 1.
Fluctuations of eGFRwere always transient because eGFR re-
turned to previous value after management of hydroelectrolytic
balance. Principal management included reducing diuretic
therapy and/or lactulose use, treating urinary tract infections,
and other less severe infections. As shown in Table 1, these
eGFR-Fwere not associatedwithworsening of renal function
during L-Tx time as demonstrated by no significant differ-
ences in eGFR-list and sCr-list versus eGFR-Tx and sCr-Tx,
median values.
Baseline eGFR is a very important nephrologic parameter
in the evaluation of renal function, in particular for the diag-
nosis of acute renal dysfunction, which is focused on eGFR/
sCr modifications from a previous value.5,16,27,28
During an episode of AKI, eGFR value shows an abrupt
drop from values previously collected usually considered a
baseline value. Therefore, AKI diagnosis or evaluations of
eGFR modifications can only be performed retrospectively.
KDIGO guideline suggests to consider as baseline the low-
est outpatient creatinine value between 7 and 365 days before
the current value.5 The so-called looking backmethod13 is de-
scribed as the best condition to consider eGFR-max as the
baseline renal function.
In our study, we identified the eGFR-max as the highest
value of eGFR among all values retrospectively collected dur-
ing a median period of 254 days, corresponding to L-Tx time.FIGURE 3. eGFR trend 5 years posttransplantation in patients with
and without AKI post-Tx.Furthermore, the retrospective assessment of eGFR-max in
outpatients with ESLD during L-Tx time has allowed the
identification of eGFR events characterized by a transient sig-
nificant reduction of eGFR more than 50%, outside KDIGO
criteria, defined as DeGFR.
These drops were found in 35% of our patients and were
not associated with the worsening of renal function during
L-Tx time, whereas drops were associated with the worse
post-Tx kidney outcome, as shown in Table 3.
In DeGFR+ group compared with DeGFR- group, we ob-
served at listing and at TxhigherMELD score due to higher bil-
irubin values and not related to a higher sCr values. This higher
MELD score reflects the advanced degree of ESLD. In these
patients, renal and hepatic functions are closely intertwined,
as confirmed by the association between renal dysfunction
and higher MELD score highlighted in previous studies.29-31
In our study, we demonstrated that patients in DeGFR+
group are sicker patients characterized by a worse degree of
liver dysfunction and particularly prone to eGFR modifica-
tion during L-Tx time.
Furthermore, eGFR drops were associated with early oc-
currence of post-Tx AKI stages 2 to 3 (P = 0.007). Although
in DeGFR+ group, we found a higher prevalence of pre-Tx
CKD, the occurrence of post-Tx AKI was not significantly
different among DeGFR+ patients with and without CKD.
We cannot exclude that eGFR drops represented undiag-
nosed episodes of AKI outside KDIGO diagnostic criteria
or occurrence of acute kidney disease (AKD). As defined by
KDIGO guideline,5 the term “acute kidney disease” (AKD)
refers to kidney damage present more than 1 month and less
than 3 months (unlike CKD).11
6 Transplantation DIRECT ■ 2017 www.transplantationdirect.comIn a study on patients affected by kidney disease with
biopsy-proven evidence of acute diffuse parenchymal dam-
age, 35% of the cases did not meet the KDIGO criteria for
AKI.32 These non-AKI cases of acute kidney damage had
similar outcomes to AKI, so the authors emphasized that
the division between AKI and AKDmay be arbitrary, as also
suggested by the KDIGO guideline.5 Moreover, in a large
study on 104 764 inpatients with de novo AKI, including
AKI stage 1 (increase in sCr ≥ 0.3 mg/dL within 48 hours),
the apparent recovery of kidney function remained an inde-
pendent risk factor for poor kidney outcome at 1 year.33
Our results seem to be in agreement with literature, in fact,
our cases could be considered as AKD patients.34 The eGFR
returned to previous value in a period no longer than
3 months and the poor outcome is confirmed by the occur-
rence of de novo post-Tx AKI.
The diagnostic accuracy for AKI could be improved by the
possible role of new biomarkers discovered in the past few
years, as urinary neutrophil gelatinase-associated lipocalin,
kidney injury molecule 1, liver fatty acid binding protein,
and interleukin-18.34 However, they are expensive and need
to be validated in general population and in patients with
cirrhosis. We expect the combination of several urinary
biomarkers and early diagnosis to significantly contribute
to the differential diagnosis of kidney dysfunction in the
near future and improve the nephrologist monitoring pre-
and post-Tx.
In conclusion, eGFR-F are common in outpatients with
ESLD who received transplantation and are not indicative
of worsening of renal function from listing to liver Tx. How-
ever, DeGFR are more frequent in patients with worse condi-
tion of ESLD and may be associated with worse post-Tx
kidney outcome.
The collection of several eGFR values, instead of consider-
ing a single eGFR value, may help to understand the dynam-
ics of variations in kidney function and may add prognostic
information. A closer nephrologicmonitoring of cirrhotic pa-
tient candidates to receive liver Tx may help to identify the
actual eGFR-max value and define DeGFR.
Calcineurin inhibitors have a crucial role in the immuno-
suppression after liver Tx and its nephrotoxicity is a well-
known risk factor of kidney dysfunction post-Tx. In our
patients, the introduction of tacrolimus was delayed after
the onset of AKI according to other transplant centers, then
the exposure to tacrolimus did not influence AKI develop-
ment in our population.35-37
This study is affected by some limitations. First, the small
sample size of the studymay affect the strength of our conclu-
sion, but this is a single-center study, and all our patientswere
listed and transplanted in the Liver Unit of Sapienza Univer-
sity of Rome. Second, the retrospective study design may be
considered a limitation, but in this case, it has represented
the best condition to evaluate the eGFR-max among several
eGFR values collected over time. Further and larger analyses
are required to evaluate the impact of pre-Tx DeGFR on
early and long-term post-Tx outcome.REFERENCES
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